Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.36% is 12% below its 5-year average of 0.42%, near the low end of its 5-year range (0.10%–1.04%).
As of the fiscal period ended Tuesday, June 30, 2026. 39.62% below its 12-month average of 0.60%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.36%.
DEBT TO ASSETS RATIO
0.36%
DEBT TO ASSETS RATIO AVG TTM
0.60%
DEBT TO ASSETS RATIO AVG 3Y
0.51%
DEBT TO ASSETS RATIO AVG 5Y
0.42%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-39.62%
CURRENT VS 3Y AVG
-28.93%
CURRENT VS 5Y AVG
-12.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 595 covered companies
CURRENT VS SECTOR MEDIAN
+264.45%
vs the sector median at left
Cardiol Therapeutics Inc.
Market Cap
$152.04M
Debt to Assets Ratio
0.36%
TTM Avg
0.60%
3Y Avg
0.51%
5Y Avg
0.42%
Market Cap
$147.54M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.37M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.21M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.64M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.30M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$145.54M
Debt to Assets Ratio
0.27%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$155.42M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $152.04M | 0.36% | 0.60% | 0.51% | 0.42% |
| Codexis, Inc. (CDXS)vs › | $152.25M | 0.60% | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | 0.00% | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $153.37M | 0.00% | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $154.21M | 0.00% | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.64M | 0.00% | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $146.30M | 0.00% | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $145.54M | 0.27% | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $155.42M | 0.06% | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $144.48M | 0.02% | N/A | N/A | N/A |
Debt/Assets
0.4%
Debt/Equity
0.00
Current Ratio
5.55
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.36% |
| 2026-03-31 | 0.37% |
| 2025-12-31 | 0.53% |
| 2025-09-30 | 1.04% |
| 2025-06-30 | 0.71% |
| 2025-03-31 | 0.59% |
| 2024-12-31 | 0.50% |
| 2024-09-30 | 0.95% |
| 2024-06-30 | 0.62% |
| 2024-03-31 | 0.54% |
| 2023-12-31 | 0.48% |
| 2023-09-30 | 0.42% |
| 2023-06-30 | 0.10% |
| 2023-03-31 | 0.12% |
| 2022-12-31 | 0.12% |
| 2022-09-30 | 0.12% |
| 2022-06-30 | 0.13% |
| 2022-03-31 | 0.14% |
| 2021-12-31 | 0.13% |
| 2021-09-30 | 0.40% |
| 2021-06-30 | 0.37% |
| 2021-03-31 | 0.70% |
| 2020-12-31 | 0.99% |
| 2020-09-30 | 0.68% |
| 2020-06-30 | 0.64% |
| 2020-03-31 | 1.37% |
| 2019-12-31 | 1.23% |
| 2019-09-30 | 1.08% |
| 2019-06-30 | 0.99% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 1.09% |
| 2018-09-30 | 96.06% |
| 2018-06-30 | 82.77% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 5.90% |
